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REVIEW
Abstract: Postmenopausal osteoporosis is a common clinical entity; its complications 
represent a signiﬁ  cant burden to society. In recent years the choice of therapies available 
for the treatment of postmenopausal osteoporosis has increased dramatically. There are a 
number of antiresorptive agents currently available including hormone replacement therapy 
(HRT), selective estrogen receptor modulators (SERMs), bisphosphonates, and dual action 
bone agents. It is difﬁ  cult to truly compare these therapies given the lack of direct head-to 
head studies. The efﬁ  cacy of antiresorptive therapies can be assessed in a number of ways 
including measurement of bone mineral density (BMD), assessment of bone turnover 
markers, and fracture reduction. Other important factors include ease of administration and 
consequent patient compliance. This article reviews the currently available antiresorptive 
agents and their effects on the above outcome measures.
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Background 
Postmenopausal osteoporosis is a common clinical entity; its complications represent 
a signiﬁ  cant burden to society. The lifetime risk of any fracture occurring in women 
from the age of 50 years is currently greater than 40% and it is anticipated that the 
prevalence of osteoporosis will rise in the coming decades as the longevity of the 
population increases. In addition to the negative impact on a patient’s level of independ-
ence and quality of life, the economic cost of osteoporotic fractures also needs to be 
taken into account. In the UK the estimated acute hospital cost of an osteoporotic hip 
fracture is approximately £12 000 sterling, with non-acute hospital costs representing 
an even larger amount. Other fractures are less expensive, at £468, £479, and £1338 
respectively for wrist, vertebral, and other fractures. The annual cost of treating all 
female osteoporotic fractures in the UK is £727 million. Assuming each male hip 
fracture costs the same as a female fracture, including these would increase the total 
costs to 942 million pounds (Dolan and Torgerson 1998). It has been predicted that 
the cost of treating osteoporotic fractures in postmenopausal women will increase to 
more than 2.1 billion pounds by 2020 (Burge 2001).
Osteoporotic fractures can have a detrimental impact on an individual’s level of 
independence, quality of life, and potential mortality. Hip fractures lead to a greater 
risk of functional impairment and institutionalization. Chronic pain and disability 
among patients with vertebral fractures are signiﬁ  cantly greater on average than 
among people without fractures, even after adjusting for co-morbid conditions that 
are common among the elderly. The risk of pain and disability increases progressively 
with the number and severity of vertebral deformities. Declines in physical function 
Comparative effects of antiresorptive agents 





Department of Rheumatology, Con-
nolly Hospital, Dublin, Ireland
Correspondence: Natasha Jordan
Department of Rheumatology, Connolly 
Hospital, Blanchardstown, Dublin 15, 
Ireland
Tel +35 316 466 271
Fax +35 316 466 282
Email natashajordan1@yahoo.co.ukClinical Interventions in Aging 2006:1(4) 378
Jordan et al
and changes in appearance with loss of height contribute to 
social isolation and loss of self-esteem (Ross 1997). 
In osteoporotic patients mortality is increased in the ﬁ  rst 
year after all major fractures, with age-standardized mortal-
ity ratios of 2.18 for proximal femoral fractures and 1.66 for 
vertebral fractures (Center et al 1999).
In recent years the choice of therapies available for the 
treatment of postmenopausal osteoporosis has increased 
dramatically. There are a number of antiresorptive agents 
currently available including hormone replacement therapy, 
selective estrogen receptor modulators, bisphosphonates, and 
dual action bone agents (Table 1).
Bone mineral density
Measurement of bone mineral density (BMD) by dual 
energy X-ray absorptiometry (DEXA) remains the gold 
standard for the diagnosis of osteoporosis and is frequently 
used as a primary end-point in osteoporosis treatment 
trials. A patient’s BMD is expressed by its relationship 
in standard deviations from two norms, the expected 
BMD of a young adult of the same sex (T score) and the 
expected BMD of an age and sex matched individual 
(Z score). There are limitations of BMD measurements in 
the assessment of osteoporosis. Analyses of clinical trials 
show an inconsistent relationship between increased spinal 
BMD and a decreased risk of vertebral fracture. Increased 
BMD accounts for less than 25% of the overall reduction in 
fracture risk in most instances. Although helpful in guiding 
decisions to initiate osteoporosis treatment, subsequent 
changes in BMD provide an imperfect indicator of treat-
ment efﬁ  cacy. Consequently, fracture risk reduction itself 
remains the most clinically relevant therapeutic outcome 
of osteoporosis therapy (Small 2005).
Bone turnover
Increasing evidence suggests that a high rate of bone turnover 
is associated with low BMD and is strongly linked to fracture 
risk. Measurement of biochemical markers of bone turno-
ver is therefore becoming a more widely used end-point in 
clinical trials in postmenopausal osteoporosis. Biochemical 
markers of bone resorption and formation can be measured 
in the blood and urine. Frequently used markers of resorp-
tion include deoxypyridinoline, which is measured in urine, 
and amino- and carboxy-terminal cross-linked telopeptides 
of type 1 collagen (NTx, CTx), which may be measured in 
serum or urine. Bone formation markers include osteocal-
cin, bone-speciﬁ  c alkaline phosphatase and amino-terminal 
propeptide of type 1 collagen. 
Early changes in biochemical markers of bone turnover 
predict BMD response to antiresorptive therapy and may 
potentially identify non-responders to therapy. Signiﬁ  -
cant decreases in both type 1 collagen N-telopeptide and 
osteocalcin are evident in women treated with antiresorp-
tive agents as early as 3 months while the percent change 
of N-telopeptide at 3 months has been shown to correlate 
with change of spinal BMD at 12 months of treatment 
(Kim et al 2005). 
Hormone replacement therapy 
The role of estrogen deﬁ  ciency in postmenopausal oste-
oporosis is well established and for many years hormone 
replacement therapy (HRT) was used as ﬁ  rst-line therapy. 
The sudden reduction in estrogen production with the meno-
pause is responsible for an accelerated phase of bone loss. 
Estrogen deﬁ  ciency at the onset of menopause is associated 
with increased production of pro-resorptive cytokines. The 
rate of bone remodelling doubles at menopause, triples 13 
years after menopause, and remains high if osteoporosis 
occurs (Recker et al 2004). The use of long-term HRT has 
been limited by evidence of association with increased risk 
of breast cancer (Beral 2003). It is now advised that HRT 
is used for the shortest time possible to prevent menopausal 
symptoms, but long-term administration for the prevention 
of osteoporosis is no longer advisable.
HRT and BMD
A number of studies have shown increased BMD at the 
lumbar spine and neck of femur in patients with established 
Table 1 Effects of antiresorptive agents on BMD and fracture 
reduction in postmenopausal women with osteoporosis
    Lumbar   Hip BMD    Risk of   Risk of 
 spine      vertebral  non-
 BMD     fracture   vertebral
       fracture 
  HRT      ↑   ↑   ↓  ↓
  Raloxifene      ↑   ↑  ↓   ↔
  Etidronate      ↑   ↑  ↓  ↔
  Alendronate      ↑  ↑  ↓  ↓
  Risedronate       ↑   ↑  ↓  ↓
  Ibandronate      ↑   ↑  ↓ Not  yet 
       ascertained 
  Strontium     ↑   ↑  ↓  ↓
Ranelate    Allow for   Allow for 
 bone    bone 
 strontium    strontium
 content   content    
Abbreviations: BMD, bone mineral density; HRT, hormone replacement therapy.Clinical Interventions in Aging 2006:1(4) 379
Antiresorptive agents in postmenopausal women
osteoporosis following treatment with HRT in either oral 
or transdermal forms. Continuous low dose estrogen and 
progesterone therapy over a 3.5 year period increased spinal 
BMD by 3.5% (p<0.001) in an intention-to-treat analysis and 
by 5.2% among patients with greater than 90% adherence 
to therapy (Recker et al 1999). Transdermal estrogen, when 
compared with placebo in a one-year study, showed a 5.3% 
versus 0.2% (p=0.007) change in BMD at the lumbar spine 
and 7.6% versus 2.1% (p = 0.03) at the femoral trochanter 
(Lufkin et al 1992). 
HRT and bone turnover
At the menopause markers of bone resorption and forma-
tion increase, but can be restored to premenopausal values 
with estrogen replacement. Combined estrogen/progestagen 
therapy compared with placebo over a 1 year period shows 
signiﬁ  cantly decreased biochemical estimates of bone resorp-
tion (fasting urinary calcium and hydroxyproline) and bone 
formation (serum alkaline phosphatase and plasma osteocal-
cin) (p<0.001). The reduction in indices of bone resorption 
was more pronounced than that in bone formation after one 
year, indicating a positive bone balance (Christiansen and 
Riis 1990). 
Transdermal estrogen uniformly decreases bone 
turnover as assessed by serum osteocalcin concentration 
and histomorphometric evaluation of iliac biopsies. 
Biopsy samples conﬁ  rmed the effect of estrogen on bone 
formation rate per bone volume (median change, −12.9% 
compared with −6.2%% per year; p=0.004) (Lufkin 
et al 1992).
In a separate study of the effectiveness of transdermal 
estrogen on BMD, patients were divided by measurement 
of whole body retention (WBR) of 99mTc-methylene 
diphosphonate into those with high and low bone turno-
ver. The response to estrogen was greater in high bone 
turnover patients than in low bone turnover patients. BMD 
in the lumbar spine increased by 5.7% and 6.6% in high 
bone turnover patients and by 2.6% and 2.7% in low bone 
turnover patients after 1 and 2 years, respectively. Hence, the 
evaluation of bone turnover may be useful to identify those 
postmenopausal osteoporotic women who may especially 
beneﬁ  t from treatment with estrogen (Gonnelli et al 1997). 
HRT and clinical outcomes 
As a result of uncertainties in the balance of risks and ben-
eﬁ  ts for hormone replacement therapy, the Women’s Health 
Initiative (WHI) was undertaken. This randomized controlled 
study of postmenopausal women observed rates of coronary 
artery disease, breast cancer, stroke, pulmonary embolism, 
endometrial cancer and fractures. Participants were randomly 
assigned to receive estrogen plus medroxyprogesterone ac-
etate or placebo. Fractures were experienced by 8.6% in the 
estrogen-progestin group and 11.1% in the placebo group 
(hazard ratio [HR] 0.76). The decreased risk of fracture at-
tributed to estrogen plus progestin appeared to be present in 
all subgroups of women examined. After a mean of 5.2 years 
the estimated HRs were as follows: coronary artery disease 
1.29, breast cancer 1.26, stroke 1.41, pulmonary embolism 
2.13, and endometrial cancer 0.83. On this basis, the project 
management group concluded that the overall health risks 
exceeded the beneﬁ  ts from use of combined estrogen and 
progestin for an average 5.2 year follow-up in healthy post-
menopausal women (Cauley et al 2003).
The reduction in fracture risk by estrogen exceeds that 
expected based on BMD alone. Estrogen therapy must be 
continued indeﬁ  nitely for preservation of its anti-fracture 
efﬁ  cacy. A decade after discontinuation of HRT, women will 
have a similar fracture risk to those who have not received 
therapy. Given the strong body of evidence supporting the 
effectiveness of HRT in preventing osteoporotic fractures, 
the challenge facing physicians is whether the beneﬁ  ts of 
HRT outweigh its risks.
Selective estrogen receptor 
modulators 
The selective estrogen receptor modulators (SERMs) exert 
estrogenic activity in some target tissues, for example 
bone, while sparing the breast and endometrium from the 
undesirable stimulation caused by estrogen and as such are 
an alternative to hormone replacement therapies for the 
treatment of postmenopausal osteoporosis. Raloxifene is 
the only SERM licensed for the treatment of osteoporosis. 
Drawbacks of this therapy are menopausal symptoms of hot 
ﬂ  ushes, breast pain and vaginal bleeding and also increased 
incidence of thromboembolic events (Cosman et al 2005; 
Layton et al 2005; Romero et al 2005).
Raloxifene and BMD
A number of studies have shown the beneficial effect 
of raloxifene on BMD in postmenopausal osteoporosis 
(Delmas et al 1997; Lufkin et al 1998; Meunier et al 1999). 
The MORE trial (Multiple Outcomes of Raloxifene) was 
a multicenter, randomized, placebo-controlled study of 
7705 postmenopausal women. Compared with placebo, 
raloxifene increased BMD in the femoral neck by 2.1% 
(60 mg) and 2.4% (120 mg) and in the spine by 2.6% (60 mg) Clinical Interventions in Aging 2006:1(4) 380
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and 2.7% (120 mg) (p<0.001 for all comparisons) (Ettinger 
et al 1999).
Raloxifene and bone turnover 
Raloxifene preserves bone mass by reducing elevated 
levels of bone turnover by mechanisms similar to those in 
postmenopausal women receiving hormone replacement 
therapy. In a randomized, controlled study of raloxifene 
and HRT, transiliac bone biopsies were obtained following 
double tetracycline labelling at baseline and 1 year. These 
samples were analyzed for changes in histologic indices 
of bone remodeling on the cancellous surface as well as 
at the endocortical subdivision of the endosteal envelope, 
the location of the greatest fraction of postmenopausal 
bone loss. BMD and biochemical markers of bone turno-
ver were also determined at baseline and 1 year. Four 
paired biopsies were obtained in the HRT group, six in 
the raloxifene group, and ﬁ  ve in the placebo group. The 
frequency of remodelling events on cancellous bone and 
rate of bone formation in both cancellous and endocortical 
bone increased in the placebo group, while these measure-
ments decreased in both drug treatment groups. Serum 
bone alkaline phosphatase, serum osteocalcin, and urine 
C-terminal cross-linking telopeptide of type I collagen 
signiﬁ  cantly decreased (p<0.05) in both active treatment 
groups, changes signiﬁ  cantly different than those seen 
with placebo (Weinstein et al 2003).
Raloxifene and fracture reduction 
The MORE trial (Multiple Outcomes of Raloxifene) at 
36 months showed a new vertebral fracture in 10.1% of 
women receiving placebo, 6.6% of those receiving 60 mg of 
raloxifene and 5.4% of those receiving 120 mg of raloxifene. 
Risk of vertebral fracture was reduced in both study groups 
treated with raloxifene (relative risk [RR] 0.7 for 60 mg, RR 
0.5 for 120 mg). However the risk of nonvertebral fracture 
for raloxifene versus placebo did not differ signiﬁ  cantly 
(Ettinger et al 1999).
In an extension of the MORE study a signiﬁ  cant effect on 
nonvertebral fractures was seen only in patients with severe 
vertebral fractures at baseline (Delmas et al 2003).
Bisphosphonates
The bisphosphonate group of drugs are considered ﬁ  rst line 
therapy for the treatment of postmenopausal osteoporosis. Bi-
sphosphonates are stable chemical analogues of an inorganic 
pyrophosphate. They inhibit osteoclastic bone resorption via 
a mechanism that differs from that of other antiresorptive 
agents. Bisphosphonates attach to bony surfaces particularly 
in sites of active resorption, reduce recruitment and activ-
ity of osteoclasts and increase their apoptosis (Rodan and 
Fleisch 1996).
Despite their structural similarities, there are important 
differences among the bisphosphonates in potency and toxic-
ity. The mechanism by which the bisphosphonates increase 
the apoptosis of osteoclasts differs. The ﬁ  rst generation of 
bisphosphonates included etidronate and tiludronate. The 
more potent second generation of bisphosphonates include 
alendronate, risedronate, and ibandronate. These nitrogen-
containing bisphosphonates interfere with the mevalonate 
pathway and protein prenylation, while other bisphospho-
nates are incorporated into nonmetabolized analogs of ad-
enosine triphosphate (ATP) (Reska and Rodan 2003, 2004; 
Rogers 2003).
Etidronate 
Etidronate was the ﬁ  rst bisphosphonate used in the treatment 
of postmenopausal osteoporosis. A seven year study deter-
mined the efﬁ  cacy and safety of cyclical oral etidronate in 
the treatment of postmenopausal osteoporosis and examined 
the effects of discontinuing treatment after 2 or 5 years of 
therapy. The incidence and rate of vertebral fractures were 
lowest in patients with the longest exposure to etidronate. 
Bone mass was maintained for at least 2 years after treatment 
with etidronate was discontinued, however, further gains in 
spinal bone mass were seen in patients who continued therapy 
(Miller et al 1997).
Etidronate is available in both oral and intravenous 
preparations. However the administration of etidronate 
by prolonged intravenous infusion was inconvenient, and 
potentially associated with thrombotic complications and 
infections. Etidronate has been largely superseded by the 
other bisphosphonates.
Alendronate and BMD 
Several studies have demonstrated the long-term efﬁ  cacy 
of alendronate in the treatment of postmenopausal 
osteoporosis. (Harris et al 1993; Liberman et al 1993; 
Chestnut et al 1995; Black et al 1996; Tucci et al 1996; 
Hosking et al 1998). 
Alendronate signiﬁ  cantly increases BMD at the lumbar 
spine, hip and total body and is well tolerated in the treat-
ment of osteoporosis in postmenopausal women. In a rand-
omized, double-blind, placebo-controlled, 2-year study, 188 
postmenopausal women showed mean changes in BMD over 
24 months with 10 mg alendronate of +7.21% +/− 0.49% Clinical Interventions in Aging 2006:1(4) 381
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for the lumbar spine, +5.27% +/− 0.70% for total hip, and 
+2.53% +/− 0.68% for total body (p<0.01) compared with 
changes of −1.35% +/− 0.61%, −1.20% +/− 0.64% and 
−0.31% +/− 0.44% at these sites, respectively, with placebo 
treatment. (Chestnut et al 1995). 
In a separate multinational study of postmenopausal 
women with lumbar spine t scores of ≤−2, subjects were 
randomly assigned to receive oral alendronate 10 mg (n=950) 
or placebo (n=958) once daily. At 12 months, mean increases 
in BMD were signiﬁ  cantly greater in the alendronate than 
the placebo group by 4.9% at the lumbar spine, 2.4% at the 
femoral neck, 3.6% at the trochanter and 3.0% for total hip 
(p≤0.001)(Pols et al 1999).
Alendronate is the only bisphosphonate with ten year 
data. Treatment with 10 mg of alendronate daily for 10 years 
produced mean increases in BMD of 13.7% at the lumbar 
spine, 10.3% at the trochanter and 5.4% at the femoral neck. 
Discontinuation of alendronate resulted in a gradual loss of 
effect, as measured by BMD and biochemical markers of 
bone remodelling (Bone et al 2004).
Alendronate and bone turnover 
To establish whether biochemical markers could be used 
to monitor alendronate treatment and predict long-term 
response in BMD, a randomized trial was undertaken in 
postmenopausal women treated with 5 mg of alendronate. 
Urine N-telopeptide cross-links of type I collagen and os-
teocalcin were measured at baseline and 6 months. Spinal, 
hip, and total body BMD was recorded at baseline and 24 
months. Reductions in biochemical marker levels at 6 months 
correlated with change from baseline in BMD at 24 months 
(coefﬁ  cient of correlation from baseline [r]=−0.28 to −0.31 
for N-telopeptide, r = −0.16 to −0.25 for osteocalcin) (Ravn 
et al 1999). 
Alendronate administered at 10 mg daily produces a 
reduction in mean urinary deoxypyridinoline/creatinine re-
duction of 47% at 3 months, and in mean serum osteocalcin 
of 53% at 6 months (Chestnut et al 1995).
Alendronate and fracture reduction 
A phase III trial comparing alendronate and placebo over 
3 years in postmenopausal women with low femoral BMD 
and at least one previous vertebral fracture at baseline 
showed a reduction in both vertebral and nonvertebral 
fractures. A lower incidence of one or more new vertebral 
fractures was detected by X-ray (8% vs 15% in the placebo 
group, RR 0.5). There were fewer clinically evident 
vertebral fractures in the alendronate group (2.3% vs 5.0%, 
RR 0.4). There was an overall lower rate of any fracture, 
including hip and wrist fractures (14% vs 18%, RR 0.7). 
(Tucci et al 1996). The reduction in fracture incidence 
attributed to alendronate is similar in postmenopausal 
women older and younger than age 75 years (Ensrud 
et al 1997).
In postmenopausal women with low BMD, but no history 
of osteoporotic fracture, alendronate increased BMD and 
reduced the number of clinical fractures by 14%, compared 
with placebo. In women with low BMD but without vertebral 
fractures, 4 years of alendronate safely increased BMD and 
decreased the risk of ﬁ  rst vertebral deformity (Cummings 
et al 1998).
To determine the effect of alendronate on the incidence 
of nonvertebral fractures, a meta-analysis was performed of 
all completed prospective, randomized, placebo-controlled 
alendronate trials of at least 2 years’ duration (5 studies). In 
the placebo group (n=590), 60 women reported nonvertebral 
fractures during 1347 patient-years at risk (overall rate, 4.45 
women with fractures per 100 patient-years at risk). In the 
alendronate group (n=1012), 73 women reported nonverte-
bral fractures during 2240 patient-years-at risk (overall rate, 
3.26 women with fractures per 100 patient-years at risk). The 
estimated cumulative incidence of nonvertebral fractures 
after 3 years was 12.6% in the placebo group and 9.0% in 
the alendronate group (Karpf et al 1997).
Risedronate and BMD
In a study of 939 postmenopausal women with T scores of 
−2 or less and at least one vertebral fracture, treated with 
5 mg of risedronate or placebo for three years, BMD at 
the lumbar spine, femoral neck, and trochanter increased 
by 5.4%, 1.6%, and 3.3%, respectively in the risedro-
nate group, as compared with 1.1%, −1.2%, and −0.7%, 
respectively in the placebo group (Harris et al 2000). In a 
pooled analysis of all randomized trials with risedronate 
in women with low BMD but with no previous vertebral 
fracture, the mean lumbosacral spine and femoral neck 
density increased by 5.3% and 2.5%, respectively (Heaney 
et al 2002). 
Risedronate and bone turnover 
Changes in the level of biochemical markers of bone 
resorption with risedronate treatment for osteoporosis 
have been examined as a potential surrogate for the 
decrease in fracture risk. A group of 693 postmenopausal 
women with at least one vertebral deformity were 
assigned to receive either 5 mg of risedronate or placebo Clinical Interventions in Aging 2006:1(4) 382
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and followed over a three year period. Reductions in 
urinary C-telopeptide (median 60%) and N-telopeptide 
(median 51%) at 3–6 months with risedronate therapy 
were significantly associated with the reduction in verte-
bral fracture risk (75% over 1 year and 50% over 3 years, 
p<0.05). The relationships between vertebral fracture 
risk and changes from baseline in C-telopeptide and 
N-telopeptide were not linear. Little further improvement 
was seen in fracture benefit below a decrease of 55%–60% 
for C-telopeptide and 35%–40% for N-telopeptide, lead-
ing the authors to surmise that there may be a level of 
bone resorption below which there is no further fracture 
benefit (Eastell et al 2003).
In a study to determine bone safety and preservation of 
normal bone formation after 5 years of risedronate treat-
ment histomorphometric assessment of paired transiliac 
bone biopsies was undertaken. No statistically signiﬁ  cant 
differences in structural or resorption parameters of bone 
were seen between risedronate and placebo treatment 
groups. Double tetracycline labels indicating continuous 
bone turnover were identiﬁ  ed in all biopsy specimens 
(Ste-Marie et al 2004).
Risedronate and fracture reduction 
The VERT (Vertebral Efﬁ  cacy with Risedronate Therapy) 
study group has shown the efﬁ  cacy of risedronate in reducing 
both vertebral and nonvertebral fractures in postmenopausal 
women with a previous vertebral fracture. The three year 
rates of new vertebral fractures were 11% and 16% in the 
risedronate and placebo groups (p=0.003). The rates of non-
vertebral fractures were 5% and 8% respectively (p=0.02) 
(Harris et al 2000). The risk of new vertebral fracture after 
5 years of risedronate therapy is reduced by 59% (p=0.01) 
(Sorensen et al 2003).
Risedronate reduces the risk of ﬁ  rst vertebral fracture in 
postmenopausal osteoporotic women. In a placebo control-
led trial of risedronate in patients without vertebral fracture 
at baseline and who had low lumbar spine BMD, the inci-
dence of ﬁ  rst vertebral fracture was 9.4% in those treated 
with placebo and 2.6% in those treated with risedronate 
at 3 years. The number of patients who would need to be 
treated to prevent one new vertebral fracture was 15 (Heaney 
et al 2002). 
A placebo controlled trial demonstrated the efﬁ  cacy 
of risedronate in preventing hip fracture in 5445 elderly 
women with osteoporosis. After three years of treatment, 
the incidence of hip fracture in patients aged 70–79 years, 
was 1.9% in the risedronate group compared with 3.2% in 
those assigned to placebo (p=0.009). However, a subset of 
patients aged 80 or older with at least one non-skeletal risk 
factor for hip fracture (poor gait or propensity to fall) was 
also examined and no signiﬁ  cant difference was found in 
fracture rate between risedronate and placebo (McClung 
et al 2001).
Alendronate versus risedronate 
The FACT study (Fosamax Actonel Comparison Trial) 
was a 1-year-head-to-head trial comparing the efficacy 
and tolerability of once weekly alendronate 70 mg and 
risedronate 35 mg for the treatment of postmenopausal 
osteoporosis. The percentage of patients who had meas-
ured BMD gains ≥3% and ≥5% after 12 months at the 
hip trochanter, total hip, femoral neck, and lumbar spine 
was analyzed. The percentage of patients who experi-
enced any bone loss, and those with measured losses 
of 3% or more at these sites after 12 months, was also 
determined. A greater percentage of alendronate- than 
risedronate-treated patients had measured BMD gains 
(≥0%) (p<0.05) at all sites at 12 months. Significantly 
more (p<0.01) alendronate- than risedronate-treated pa-
tients had measured gains in BMD ≥3% and ≥5% at the 
hip trochanter, total hip, and lumbar spine. Significantly 
more (p<0.05) risedronate- than alendronate-treated 
patients had an apparent loss of BMD (>0% and ≥3% 
loss) at the same sites.
The percentage of patients achieving reductions in uri-
nary N-telopeptide of type 1 human collagen (NTX) ≥40%, 
and serum C-telopeptide of type 1 collagen (CTx) ≥60%, 
bone-speciﬁ  c phosphatase (BSAP) ≥30%, and N terminal 
propeptide of type 1 procollagen (P1NP) ≥50% at 3 months 
and 12 months was also determined. After 3 months, signiﬁ  -
cantly more alendronate- than risedronate-treated patients 
achieved predeﬁ  ned reductions in all biochemical markers 
(p<0.001). 
The clinical signiﬁ  cance of these BMD and bone 
turnover ﬁ  ndings is unclear as no fracture data was ac-
cumulated in the study (Sebba et al 2004). The FACT 
study was sponsored by Merck Sharp Dome, the makers 
of alendronate. In patients aged 70–79 years, risedronate 
reduces the risk of hip fracture by 60% (McClung et al 
2001). Alendronate reduces hip fracture by 51% in patients 
aged 55–81 years (Black et al 1996). These studies are 
not directly comparable given the different age groups of 
the patients involved. A meta-analysis of bisphosphonate 
therapy in preventing hip fractures shows a number needed 
to treat of 29 for risedronate and 91 for alendronate therapy Clinical Interventions in Aging 2006:1(4) 383
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(Deal 2002). When compared with calcitonin, risedronate 
has a 68% RR reduction in nonvertebral fractures at 
6 months, while alendronate has a 28% RR reduction 
(Watts et al 2004).
Ibandronate introduction
Adherence to therapy is a concern in postmenopausal 
osteoporosis. Reducing oral bisphosphonate-dosing 
frequency is one measure available to improve this. It 
has previously been shown that postmenopausal women 
prescribed a weekly bisphosphonate had signiﬁ  cantly 
better compliance than those taking daily bisphosphonates 
(Cramer et al 2005). However, compliance and persistence 
rates for both daily and weekly regimens are suboptimal, 
suggesting that less frequent dosing intervals may provide 
an opportunity to further improve the consistent use of 
bisphosphonate therapy.
Ibandronate is a potent, nitrogen-containing bisphos-
phonate. It can be administered either orally or as an 
intravenous injection, with a between-dose interval of 
greater than two months. In addition to increased conven-
ience, the availability of once-monthly ibandronate may 
improve tolerability by reducing the potential for upper 
gastrointestinal irritation that can result from frequent, 
repeated exposure. 
Ibandronate and BMD
The BONE (oral iBandronate Osteoporosis verte-
bral fracture trial in North America and Europe) trial 
determined that ibandronate with dose-free intervals 
of greater than 2 months provided similar anti-fracture 
efﬁ  cacy to daily dosing. Daily and intermittent iband-
ronate signiﬁ  cantly increased BMD in the spine in both 
North American (5.4% and 4.4% vs baseline with daily 
and intermittent ibandronate, respectively) and European 
(7.1% and 6.3% vs baseline, respectively) populations. 
Signiﬁ  cant increases were also observed for total hip BMD 
(2.6% and 3.7% vs baseline for daily, and 2.5% and 3.1% 
for intermittent; North American and European popula-
tions, respectively) (Chestnut et al 2005).
The monthly oral ibandronate therapy in postmeno-
pausal osteoporosis (MOBILE) study compared once-
monthly and daily ibandronate. A total of 1609 women 
were assigned to one of four oral ibandronate regimens: 
2.5 mg daily, 50/50 mg monthly (single doses, consecutive 
days), 100 mg monthly or 150 mg monthly. After 1 year, 
lumbar spine BMD increased by 3.9%, 4.3%, 4.1%, 
and 4.9% in the 2.5 mg, 50/50 mg, 100 mg, and 150 mg 
arms, respectively. All monthly regimens were proven 
non-inferior, and the 150 mg regimen superior, to the 
daily regimen. All monthly regimens produced similar hip 
BMD gains, which were larger than those with the daily 
regimen (Miller et al 2005).
Two year results from the MOBILE study showed 
substantial increases in lumbar spine BMD (5.0%, 
5.3%, 5.6% and 6.6%) in the daily and once-monthly 
groups (50 mg + 50 mg, 100 mg and 150 mg), respectively. 
Substantial increases in proximal femur BMD (total hip, 
femoral neck, trochanter) were observed in all groups; 
150 mg produced the most pronounced effect (p<0.05 vs 
daily) (Reginster et al 2006).
Ibandronate and bone turnover 
The BONE study demonstrated that ibandronate, adminis-
tered both daily and intermittently, produced comparable, 
signiﬁ  cant decreases in biochemical markers of bone turno-
ver. A reduction in urinary excretion of C-telopeptide levels 
of 53.5% and 67.1% versus baseline for daily, and 50.0% 
and 53.8% for intermittent (North American and European 
populations, respectively) was observed (p<0.004 for all cited 
measurements in each ibandronate group versus placebo) 
(Chestnut et al 2005). The MOBILE trial showed similar 
decreased levels of C-telopeptide in all regimens (daily 
and once-monthly groups 50 + 50 mg, 100 mg and 150 mg) 
(Cramer et al 2005). The 150mg regimen consistently 
produced greater C-telopeptide suppression than the 100 mg 
and daily regimens (Miller et al 2005).
Ibandronate and fracture reduction 
In the BONE study consistent, signiﬁ  cant efﬁ  cacy in fracture 
prevention was observed in the North American (new ver-
tebral fracture risk reduction: 60% and 54% with daily and 
intermittent ibandronate, respectively) and European patient 
populations (50% and 48%, respectively). Both ibandronate 
regimens also signiﬁ  cantly reduced the incidence of new, 
worsening, and acute clinical, vertebral fractures (Chestnut 
et al 2005). 
Zoledronate
Zoledronate is currently the most potent bisphosphonate 
licensed for the treatment of malignant hypercalcemia, 
but is not yet licensed for the treatment of osteoporosis. A 
placebo controlled trial of zoledronate, administered at 3 or 
6 monthly intervals to postmenopausal women with oste-
oporosis increased BMD in all dosing regimens and induced Clinical Interventions in Aging 2006:1(4) 384
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a sustained reduction in bone resorption markers (Reid et al 
2002). A phase III study of zoledronate with fracture as end-
point is currently ongoing.
Dual action bone agents – 
strontium ranelate
Strontium ranelate has a unique dual mechanism of action 
in that it simultaneously increases bone formation and 
decreases bone resorption. It is an orally active agent 
consisting of two atoms of stable strontium and an organic 
moiety, namely ranelic acid. In vitro studies show that 
strontium ranelate increases bone formation by increasing 
osteoblast precursor replication and collagen synthesis, 
and reduces bone resorption by decreasing osteoclast dif-
ferentiation and resorption activity (Baron and Tsouderos 
2002; Takahashi et al 2003). The presence of strontium in 
bone inﬂ  uences BMD measurement by DEXA scanning. 
An adjustment factor (10% overestimation for 1mol/mol% 
strontium) can be used to calculate the true BMD (Nielsen 
et al 1999).
Strontium ranelate and BMD 
Two randomized studies have investigated the effect of 
strontium ranelate on BMD in postmenopausal women with 
osteoporosis, using BMD at the lumbar spine as a primary 
efﬁ  cacy endpoint and femoral BMD as a secondary outcome 
measure.
The STRATOS study (Strontium ranelate: dose-de-
pendent effects in established postmenopausal vertebral 
osteoporosis) enrolled 353 osteoporotic women with at least 
one previous vertebral fracture and a lumbar T-score <−2.4. 
Patients were randomized to receive placebo, 0.5 g, 1 g, or 
2 g of strontium daily for 2 years. Lumbar BMD, adjusted 
for bone strontium content, increased in a dose-dependent 
manner from 1.4% with 0.5 g/day strontium to 3.0% with 
2 g/day strontium, which was signiﬁ  cantly higher than pla-
cebo (p<0.01) (Meunier et al 2002).
The prevention of early postmenopausal bone loss by 
strontium ranelate (PREVOS) trial showed at two years, 
strontium ranelate (1 g/day) signiﬁ  cantly increased lumbar 
BMD compared with placebo (+5.53%; p<0.001) for meas-
ured values and also for values adjusted for bone strontium 
content (+1.41%; p<0.05). Femoral neck and total hip BMD 
were also signiﬁ  cantly increased compared with placebo, 
but values adjusted for strontium content were not given 
(Reginster et al 2002).
Strontium ranelate and bone 
turnover 
Clinical trials have mainly focused on fracture reduction 
outcomes, however in both the SOTI (Spinal Osteoporosis 
Therapeutic Intervention) and TROPOS (Treatment of Pe-
ripheral Osteoporosis) studies, bone alkaline phosphatase 
increased and C-telopeptide decreased in all patients treated 
with strontium ranelate compared with placebo at all time 
points (Meunier et al 2004; Reginster et al 2005).
Strontium ranelate and fracture 
reduction 
The anti-fracture effect of strontium ranelate has been dem-
onstrated in two placebo-controlled phase III studies. 
The SOTI trial demonstrated a reduced relative risk of 
new vertebral fracture over three years in postmenopausal 
females with established osteoporosis and a previous ver-
tebral fracture. New vertebral fractures occurred in fewer 
patients in the strontium ranelate group than the placebo 
group, with a risk reduction of 49% in the ﬁ  rst year of treat-
ment and 41% during the three-year study period (RR, 0.59) 
(Meunier et al 2004).
The TROPOS study examined the effect of long-term 
treatment with strontium ranelate on vertebral and non-
vertebral fractures in 5000 postmenopausal women with 
osteoporosis. Nonvertebral fracture was the predetermined 
main evaluation criterion. Over three years, treatment with 
strontium ranelate was associated with a 16% reduction 
in nonvertebral fractures (hip, wrist, pelvis, sacrum, ribs) 
relative to placebo. In a subgroup of women who were 
designated as being at high risk of nonvertebral fractures on 
account of their age and femoral BMD, the relative risk of 
hip fracture was reduced by 36% following treatment with 
strontium ranelate. The risk of sustaining a new vertebral 
fracture was reduced by 45% over 1 year and 39% over 3 
years (Reginster et al 2005).
In patients over 80 years of age at inclusion, a pooled 
analysis of SOTI and TROPOS studies showed a reduction 
in RR of sustaining a new vertebral fracture of 32% over 3 
years of strontium ranelate treatment (incidence of 19.1% 
with strontium ranelate and 26.5% with placebo).
Conclusion
Nonpharmacologic measures should be recommended 
to all postmenopausal women, including adequate exer-
cise, a calcium rich diet, smoking cessation and avoid-
ance of excessive alcohol intake. Calcium and vitamin D Clinical Interventions in Aging 2006:1(4) 385
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supplementation are vital in those found to be deﬁ  cient. 
Most osteoporotic fractures other than vertebral fractures 
are associated with falls. Factors such as muscle weakness, 
impaired vision, poor balance, and the use of medications 
that can cause drowsiness need to be taken into account in 
postmenopausal women at risk of osteoporotic fractures. A 
greater emphasis needs to be placed on fall prevention and 
patient education. 
When used in association with such nonpharmacologic 
measures, antiresorptive therapy is effective in reducing 
fracture risk and the signiﬁ  cant associated morbidity and 
mortality of postmenopausal osteoporosis.For many years the 
mainstay of treatment for postmenopausal osteoporosis had 
been HRT. However given concerns regarding risk beneﬁ  t 
ratio, HRT is no longer used as ﬁ  rst line therapy. SERMs used 
as a single agent have proven efﬁ  cacy in fracture reduction 
and increasing BMD and may yet play an additional role as 
combination therapy with other antiresorptive agents.
The ﬁ  rst generation bisphosphonates have been largely 
superseded by second generation agents such as risedronate 
and alendronate that have superior fracture reduction ef-
ﬁ  cacy, particularly at the hip. The advent of once weekly 
bisphosphonate therapy was a major advance in improving 
patient compliance. The debate continues with regard to 
the superiority of continuous or intermittent treatment with 
bisphosphonates. The development of bisphosphonate thera-
pies with longer dosage free intervals is an area of ongoing 
interest. Antifracture efﬁ  cacy and safety of these intermittent 
bisphosphonate regimens needs to be demonstrated. Regard-
less of which bisphosphonate is used, there is a paucity of 
long-term data suggesting the optimal duration of treatment 
with bisphosphonate therapy.
The dual action bone agent strontium ranelate is an al-
ternative for the treatment of postmenopausal osteoporosis. 
As antifracture efﬁ  cacy in the lumbar spine has been demon-
strated with this agent, it should be considered for those most 
at risk of vertebral fracture. Another potential indication for 
the use of strontium ranelate is in those who are intolerant 
of bisphosphonate therapy
Anabolic agents are now being employed in the treat-
ment of postmenopausal osteoporosis. Recombinant 
human parathyroid hormone (PTH) stimulates bone 
formation, in contrast to antiresorptive agents. Recent 
investigations involving PTH, alone and in combination 
or sequential regimens with antiresorptive agents, have 
provided a greater understanding of the place of PTH in 
the armamentarium against osteoporosis. These studies 
indicate that adding a bisphosphonate to PTH in previously 
untreated individuals does not produce additional bone 
beneﬁ  t (Black et al 2003). However, sequential use of PTH 
followed by alendronate is highly effective at increasing 
BMD (Black et al 2005). 
Potential novel antiresorptive agents are undergoing 
research. Recent new insights in our understanding of 
osteoclast differentiation have focused our attention on 
osteoprotegerin and receptor activator of NF-κB (RANK) 
ligand. A fully human monoclonal antibody to RANK 
ligand has been developed which has proven antiresorp-
tive effects in reducing urinary N-telopeptide (Bekker et al 
2004). Cathepsin K, a protease secreted by osteoclasts, is 
another potential therapeutic target for the treatment of 
postmenopausal osteoporosis. Estrogen deﬁ  cient primates 
injected subcutaneously with cathepsin K inhibitor 
were shown to have a 42% reduction in C-terminal 
telopeptide and a 34% reduction in N-telopeptide (Stroup 
et al 2001).
From this overview we can clearly see that there are a 
large number of effective treatments currently available 
for postmenopausal osteoporosis. Despite this it is dif-
ﬁ  cult to truly compare these therapies given the lack of 
direct head-to head studies. A number of questions remain 
unanswered. The possibility of combining anti-resorp-
tive therapies has not as of yet been fully explored. This 
therapeutic option may further improve clinical outcomes 
and fracture reduction. 
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